SG11201702185UA - PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS - Google Patents
PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTSInfo
- Publication number
- SG11201702185UA SG11201702185UA SG11201702185UA SG11201702185UA SG11201702185UA SG 11201702185U A SG11201702185U A SG 11201702185UA SG 11201702185U A SG11201702185U A SG 11201702185UA SG 11201702185U A SG11201702185U A SG 11201702185UA SG 11201702185U A SG11201702185U A SG 11201702185UA
- Authority
- SG
- Singapore
- Prior art keywords
- intermediates
- processes
- preparation
- c5ar antagonists
- c5ar
- Prior art date
Links
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 title 1
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462057107P | 2014-09-29 | 2014-09-29 | |
| PCT/US2015/052697 WO2016053890A1 (en) | 2014-09-29 | 2015-09-28 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201702185UA true SG11201702185UA (en) | 2017-04-27 |
Family
ID=55583729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702185UA SG11201702185UA (en) | 2014-09-29 | 2015-09-28 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9745268B2 (en) |
| EP (2) | EP3682879B1 (en) |
| JP (1) | JP6898229B6 (en) |
| KR (2) | KR20230149873A (en) |
| CN (2) | CN106999481B (en) |
| AU (2) | AU2015324111B2 (en) |
| BR (1) | BR112017006232B1 (en) |
| CA (2) | CA2960733C (en) |
| DK (1) | DK3200791T3 (en) |
| ES (2) | ES2926828T3 (en) |
| IL (1) | IL251061B (en) |
| MA (1) | MA52308A (en) |
| MX (2) | MX368492B (en) |
| NZ (2) | NZ767823A (en) |
| PL (1) | PL3200791T3 (en) |
| PT (1) | PT3200791T (en) |
| RU (1) | RU2712233C2 (en) |
| SG (1) | SG11201702185UA (en) |
| WO (1) | WO2016053890A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010075257A1 (en) | 2008-12-22 | 2010-07-01 | Chemocentryx, Inc. | C5ar antagonists |
| WO2011163640A1 (en) * | 2010-06-24 | 2011-12-29 | Chemocentryx, Inc. | C5ar antagonists |
| MA52308A (en) * | 2014-09-29 | 2021-02-24 | Chemocentryx Inc | METHODS AND INTERMEDIARIES FOR PREPARING C5AR ANTAGONISTS |
| RU2742888C2 (en) | 2016-01-14 | 2021-02-11 | Кемосентрикс, Инк. | Method of treating c3-glomerulopathy |
| MA50537A (en) * | 2017-10-30 | 2021-04-07 | Chemocentryx Inc | DEUTERATED COMPOUNDS USED AS IMMUNOMODULATORS |
| SG11202011961YA (en) | 2018-06-07 | 2020-12-30 | Chemocentryx Inc | Dosing and effect of c5a antagonist with anca-associated vasculitis |
| HUE062551T2 (en) | 2018-11-30 | 2023-11-28 | Chemocentryx Inc | Capsule formulations |
| KR102207333B1 (en) * | 2019-09-09 | 2021-01-27 | 성균관대학교산학협력단 | Novel Production Method for Quadruple Cyclic Compounds |
| IL292317A (en) * | 2019-11-08 | 2022-06-01 | Chemocentryx Inc | Free base crystalline form of a complement component c5a receptor |
| CN114641288A (en) | 2019-11-08 | 2022-06-17 | 凯莫森特里克斯股份有限公司 | Amorphous form of complement component C5a receptor |
| IL292371A (en) | 2019-11-08 | 2022-06-01 | Chemocentryx Inc | Salt forms of a complement component c5a receptor |
| WO2022078269A1 (en) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Crystal form of avacopan, preparation method therefor, and use thereof |
| EP4137133A1 (en) | 2021-08-19 | 2023-02-22 | Sandoz AG | Crystalline form of avacopan |
| WO2022263263A1 (en) | 2021-06-16 | 2022-12-22 | Sandoz Ag | Crystalline form of avacopan |
| CN113957106B (en) * | 2021-11-03 | 2024-04-19 | 暨明医药科技（苏州）有限公司 | Avacopan and preparation method of intermediate thereof |
| CN114262291B (en) * | 2022-01-04 | 2023-05-19 | 重庆医科大学 | Synthesis method of atorvastatin |
| WO2023158722A2 (en) | 2022-02-16 | 2023-08-24 | Teva Pharmaceuticals International Gmbh | Processes for preparation of avacopan and intermediates thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4686100A (en) | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
| WO2000012074A2 (en) | 1998-08-28 | 2000-03-09 | Scios Inc. | Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
| RU2197288C2 (en) | 1999-08-03 | 2003-01-27 | Тверская медицинская академия | Method for treating patients for chronic glomerulonephritis |
| WO2001085720A1 (en) | 2000-05-05 | 2001-11-15 | Smithkline Beecham Corporation | Novel anti-infectives |
| ATE485266T1 (en) | 2000-08-10 | 2010-11-15 | Mitsubishi Tanabe Pharma Corp | 3-SUBSTITUTED UREA DERIVATIVES AND THEIR MEDICAL USE |
| EP1318140B9 (en) | 2000-09-14 | 2014-05-21 | Mitsubishi Tanabe Pharma Corporation | Novel amide derivatives and medicinal use thereof |
| ATE404553T1 (en) | 2000-09-29 | 2008-08-15 | Neurogen Corp | HIGH AFFINE SMALL MOLECULE C5A RECEPTOR MODULATORS |
| SE524438C2 (en) | 2000-10-05 | 2004-08-10 | Magnus Georg Goertz | Remote controlled door-related locking arrangement, first and second computer program products, carrying medium and a computer-soluble medium |
| DE10231789A1 (en) | 2001-07-19 | 2003-02-06 | Luk Lamellen & Kupplungsbau | Clutch release for motor vehicle transmission has master cylinder and slave cylinder with additional electrically controlled valve to control clutch locking when stationary |
| US7432356B2 (en) | 2001-08-17 | 2008-10-07 | Genentech, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b |
| TWI265164B (en) | 2001-09-21 | 2006-11-01 | Mitsubishi Pharma Corp | 3-substituted-4-pyrimidone derivatives |
| ITMI20012025A1 (en) | 2001-09-28 | 2003-03-28 | Dompe Spa | QUATERNARY AMMONIUM SALTS OF OMEGA-AMINO ALKYLAMIDS OF R 2-ARY-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| CA2479928A1 (en) | 2002-03-28 | 2003-10-09 | Neurogen Corporation | Substituted biaryl amides as c5a receptor modulators |
| WO2003082828A1 (en) | 2002-03-28 | 2003-10-09 | Neurogen Corporation | Substituted tetrahydroisoquinolines as c5a receptor modulators |
| WO2003084524A1 (en) | 2002-03-29 | 2003-10-16 | Neurogen Corporation | Combination therapy for the treatment of conditions with pathogenic inflammatory components |
| US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| AU2003257094A1 (en) | 2002-08-08 | 2004-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
| US7169775B2 (en) | 2002-08-21 | 2007-01-30 | Neurogen Corporation | Amino methyl imidazoles as C5a receptor modulators |
| FR2846654A1 (en) | 2002-11-05 | 2004-05-07 | Servier Lab | New dihydro-4(1H)-pyridinone derivatives are useful in the treatment of cognitive disorders, neurodegenerative diseases and pain |
| US7455837B2 (en) | 2002-11-05 | 2008-11-25 | The Regents Of The University Of Michigan | Compositions and methods for the diagnosis and treatment of sepsis |
| CA2504941C (en) | 2002-11-08 | 2012-06-26 | Neurogen Corporation | 3-substituted-6-aryl pyridines |
| AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
| EP1638935A1 (en) | 2003-06-19 | 2006-03-29 | Pfizer Products Inc. | Nk1 antagonist |
| US20060154917A1 (en) | 2003-07-03 | 2006-07-13 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| WO2006012226A2 (en) | 2004-06-24 | 2006-02-02 | Incyte Corporation | N-substituted piperidines and their use as pharmaceuticals |
| EP1621536A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| WO2006071958A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| BRPI0607756A2 (en) | 2005-02-18 | 2010-05-18 | Astrazeneca Ab | compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, method for inhibiting bacterial DNA gyrase and / or topoisomerase iv in a warm-blooded animal, use of a compound or a pharmaceutically acceptable salt thereof, and process for preparing compounds or pharmaceutically acceptable salts thereof |
| WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| WO2007051062A2 (en) | 2005-10-28 | 2007-05-03 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
| LT1951663T (en) | 2005-11-24 | 2016-11-10 | Dompé Farmaceutici S.P.A. | (r)-arylkylamino derivatives and pharmaceutical compositions containing them |
| KR20080110800A (en) | 2006-03-15 | 2008-12-19 | 알렉시온 파마슈티칼스, 인코포레이티드 | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| WO2008022060A2 (en) | 2006-08-14 | 2008-02-21 | Novartis Ag | Imidazo-pyridine derivatives for modulating protein kinase activity |
| US8198266B2 (en) | 2006-10-31 | 2012-06-12 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Use of an EGFR antagonist for the treatment of glomerolonephritis |
| WO2009004650A1 (en) | 2007-06-29 | 2009-01-08 | Torrent Pharmaceuticals Ltd. | Novel substituted piperidones as hsp inducers |
| EP2331525A4 (en) | 2008-08-11 | 2013-01-02 | Harvard College | Halofuginone analogs for inhibition of trna synthetases and uses thereof |
| AU2009290137A1 (en) | 2008-09-03 | 2010-03-11 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
| US20100074863A1 (en) | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
| CA2742802C (en) | 2008-11-10 | 2019-11-26 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| WO2010075257A1 (en) | 2008-12-22 | 2010-07-01 | Chemocentryx, Inc. | C5ar antagonists |
| US20110275639A1 (en) * | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| US20120252792A1 (en) | 2009-09-17 | 2012-10-04 | The Regents Of The University Of Michigan | Methods and compositions for modulating rho-mediated gene transcription |
| WO2011163640A1 (en) * | 2010-06-24 | 2011-12-29 | Chemocentryx, Inc. | C5ar antagonists |
| EP2864322B1 (en) | 2012-06-20 | 2016-04-27 | Novartis AG | Complement pathway modulators and uses thereof |
| US20160060351A1 (en) | 2013-05-08 | 2016-03-03 | Novo Nordisk A/S | Use of C5AR Antagonists |
| MA52308A (en) | 2014-09-29 | 2021-02-24 | Chemocentryx Inc | METHODS AND INTERMEDIARIES FOR PREPARING C5AR ANTAGONISTS |
| RU2742888C2 (en) | 2016-01-14 | 2021-02-11 | Кемосентрикс, Инк. | Method of treating c3-glomerulopathy |
| RU2748260C2 (en) | 2016-04-04 | 2021-05-21 | Кемосентрикс, Инк. | SOLUBLE C5aR ANTAGONISTS |
| AU2021410668A1 (en) | 2020-12-21 | 2023-07-06 | Chemocentryx, Inc. | Treatment of c3 glomerulopathy using a c5a inhibitor |
-
2015
- 2015-09-28 MA MA052308A patent/MA52308A/en unknown
- 2015-09-28 BR BR112017006232-1A patent/BR112017006232B1/en active IP Right Grant
- 2015-09-28 MX MX2017003789A patent/MX368492B/en active IP Right Grant
- 2015-09-28 ES ES20160995T patent/ES2926828T3/en active Active
- 2015-09-28 KR KR1020237035689A patent/KR20230149873A/en active Application Filing
- 2015-09-28 CN CN201580052937.6A patent/CN106999481B/en active Active
- 2015-09-28 AU AU2015324111A patent/AU2015324111B2/en active Active
- 2015-09-28 SG SG11201702185UA patent/SG11201702185UA/en unknown
- 2015-09-28 CA CA2960733A patent/CA2960733C/en active Active
- 2015-09-28 DK DK15845610.3T patent/DK3200791T3/en active
- 2015-09-28 ES ES15845610T patent/ES2802428T3/en active Active
- 2015-09-28 KR KR1020177011789A patent/KR102593431B1/en active IP Right Grant
- 2015-09-28 JP JP2017516679A patent/JP6898229B6/en active Active
- 2015-09-28 WO PCT/US2015/052697 patent/WO2016053890A1/en active Application Filing
- 2015-09-28 US US14/867,669 patent/US9745268B2/en active Active
- 2015-09-28 EP EP20160995.5A patent/EP3682879B1/en active Active
- 2015-09-28 CN CN202110432100.1A patent/CN113121415A/en active Pending
- 2015-09-28 NZ NZ767823A patent/NZ767823A/en unknown
- 2015-09-28 RU RU2017114960A patent/RU2712233C2/en active
- 2015-09-28 CA CA3220371A patent/CA3220371A1/en active Pending
- 2015-09-28 NZ NZ730123A patent/NZ730123A/en unknown
- 2015-09-28 PL PL15845610T patent/PL3200791T3/en unknown
- 2015-09-28 EP EP15845610.3A patent/EP3200791B1/en active Active
- 2015-09-28 PT PT158456103T patent/PT3200791T/en unknown
-
2017
- 2017-03-09 IL IL251061A patent/IL251061B/en active IP Right Grant
- 2017-03-23 MX MX2019011911A patent/MX2019011911A/en unknown
- 2017-07-25 US US15/659,468 patent/US10266492B2/en active Active
-
2019
- 2019-03-21 US US16/360,195 patent/US10532982B2/en active Active
- 2019-12-06 US US16/706,296 patent/US20200354320A1/en not_active Abandoned
-
2021
- 2021-06-22 AU AU2021204209A patent/AU2021204209B2/en active Active
-
2022
- 2022-02-08 US US17/667,289 patent/US11845729B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251061A0 (en) | Processes and intermediates in the preparation of c5ar antagonists | |
| IL279606A (en) | Anti-trem2 antibodies and methods of use thereof | |
| HK1243102A1 (en) | Anti-cd79b antibodies and methods of use | |
| IL250415B (en) | Anti-pdl- antibodies and methods of use thereof | |
| HRP20181359T1 (en) | Anti-jagged1 antibodies and methods of use | |
| IL251868B (en) | Anti-tim3 antibodies and methods of use | |
| GB201421847D0 (en) | Dispensers and methods of use thereof | |
| IL251165A0 (en) | Anti-il-1beta antibodies and methods of use | |
| IL247754A0 (en) | Anti-mcam antibodies and associated methods of use | |
| IL247315A0 (en) | Anti-acth antibodies and use thereof | |
| HK1250146A1 (en) | Anti-pre-bcr antagonists and methods | |
| IL251286A0 (en) | Anti-pdgf-b antibodies and methods of use | |
| ZA201604870B (en) | Recombinant microorganisms and methods of use thereof | |
| HK1246288A1 (en) | S1pr2 antagonists and uses therefor | |
| IL247448A0 (en) | Peptides and methods of use | |
| GB201509977D0 (en) | Dispensers and methods of use thereof | |
| PL3229772T3 (en) | 6-aryl-9-glycosylpurines and use thereof | |
| GB201404133D0 (en) | Garment and method of use thereof |